Researchers have identified "a new way that cancer cells are hijacking innate immune cells to promote metastasis," Mikala Egeblad told BioWorld Today.more »
Whether PAPs are a boon or a boondoggle is in the eye of the beholder. For the U.S. patients they help to get access to expensive drugs, PAPs literally can be a life-saver. more »
Widely regarded as a powerhouse among patient advocacy groups, the Cystic Fibrosis Foundation “is a bit unique," said the CFF's Mary Dwight.
The rise of a complex and lucrative specialty drug market in the U.S. has created not only new opportunities for drugmakers, but also new challenges. With insurers tightening the reins on specialty drug coverage, drugmakers have turned to PAPs.
- PAPs may be a lifeline, but they're not the final answer
- Curing the sticker shock of new gene, cellular therapies
- Ablynx shares fall as Abbvie passes on vobarilizumab in RA
- Tight FIT: Lone responder in Rigel placebo set turns phase III, but plan intact
- 'Gene therapy in a box' could allow point-of-car...
- 3Sbio makes foray into China's diabetes market via Astrazeneca deal
- Hua's GKA passes POC; promise for growing diabetic space in China
- Profitability is in sight for Admedus with Vascucel approval
- Kinase inhibition shown effective in BRK-positive breast cancers
- Transthera nabs $10M to build NCE platform via d...
Partnership and licensing deal volume (199) and their potential values, totaling more than $19 billion, in the third quarter were about the same as those recorded in the second quarter, providing further evidence that the biopharma sector has not lost its appetite for dealmaking and those transactions are maintaining their torrid pace to eclipse the number and volume totals racked up last year.
"Basically, it's not easy to define what will serve humanity."
So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.
The Nobel Assembly followed suit in recognizing the importance of Ohsumi's work, awarding him the 2016 Nobel Prize in Physiology or Medicine to "for his discoveries of mechanisms for autophagy."READ MORE »
- 'Gene therapy in a box' could allow point-of-care cell transduction »
- Simplicity up front enables higher rate of gene correction »
- Kinase inhibition shown effective in BRK-positive breast cancers »
- Cell-based studies bring toxicity insights »
- Takes two taus to tango, but they don't tangle »
- Herb extract effective against AML in phase II »
- Old enzyme gets new job in cellular injury »
- Dual treatment efficacy in TBI via low CO levels »
- KRAS-mutated tumors sensitive to blocking housekeeping function »
- Left on the garbage heap of the 114th Congress?September 02, 2016 | 4:57 PM | Posted by: Mari Serebrov
- Will biosimilar carve-outs put R&D for older MAbs on ice?August 11, 2016 | 10:47 PM | Posted by: Mari Serebrov
- Ethically speaking: What’s the right thing to do?July 29, 2016 | 7:41 PM | Posted by: Lynn Yoffee
- For the birds, or the BlackBerries: Titles to intrigue and entertain in BioWorld’s 10th Annual Summer Reading ListJune 01, 2016 | 7:52 PM | Posted by: Marie Powers
- An end to Charlotte’s web?May 10, 2016 | 9:09 PM | Posted by: Mari Serebrov
Partners in Focus
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter